International Events 2011.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 39
- Publication type:
- Article
Works matching IS 1759832X AND DT 2011 AND VI 3 AND IP 1
Results: 31
1
2
A Phase 1/2 study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 37
- Publication type:
- Article
3
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, Phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 36
- Publication type:
- Article
4
Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 35
- Publication type:
- Article
5
Percutaneous renal cryoablation: local control at mean 26 months of follow-up.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 34
- Publication type:
- Article
6
RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 33
- Publication type:
- Article
7
The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 32
- Publication type:
- Article
8
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 31
- Publication type:
- Article
9
Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.
- Published in:
- 2011
- Publication type:
- Opinion
10
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib Phase 3 Treatment Approaches in Renal Cancer Global Evaluation Trial.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 29
- Publication type:
- Article
11
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 28
- Publication type:
- Article
12
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from Phase III TARGET.
- Published in:
- 2011
- Publication type:
- Opinion
13
Brain natriuretic peptide precursor (NTpro- BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 27
- Publication type:
- Article
14
A Phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 26
- Publication type:
- Article
15
Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 25
- Publication type:
- Article
16
How to select targeted therapy in renal cell cancer.
- Published in:
- 2011
- Publication type:
- Opinion
17
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 24
- Publication type:
- Article
18
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 23
- Publication type:
- Article
19
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 22
- Publication type:
- Article
20
Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer.
- Published in:
- 2011
- Publication type:
- Opinion
21
Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
- Published in:
- 2011
- Publication type:
- Opinion
22
Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 19
- Publication type:
- Article
23
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 18
- Publication type:
- Article
24
Surgery for renal cell carcinoma metastases.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 17
- Publication type:
- Article
25
Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 16
- Publication type:
- Article
26
Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 15
- Publication type:
- Article
27
The value of histologic subtyping on outcomes of clear cell and papillary renal cell carcinomas: a meta-analysis.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 14
- Publication type:
- Article
28
A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 14
- Publication type:
- Article
29
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factortargeted therapy.
- Published in:
- 2011
- By:
- Publication type:
- Opinion
30
Pazopanib: An Overview of its Development as a Therapy for Patients with Metastatic Renal Cell Carcinoma.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 1
- By:
- Publication type:
- Article
31
Foreword.
- Published in:
- Current Medical Literature: Kidney Cancer, 2011, v. 3, n. 1, p. 1
- Publication type:
- Article